Assay Shows Potential in Predicting Ovarian Cancer Response to Chemotherapy

Assay Shows Potential in Predicting Ovarian Cancer Response to Chemotherapy
A new assay that grows patients' cancer tissue in the lab and tests for treatment sensitivity may be able to spot ovarian cancer patients likely to respond best to first-line chemotherapy, a study showed. The ex vivo 3D cell culture (EV3D) assay, developed by Kiyatec, may lead to better informed treatment decisions and superior patient outcomes. The study, "Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer," was published in the journal Scientific Reports. First-line chemotherapy is initially effective for as many as 80% of ovarian cancer patients, but most eventually relapse. Figuring out which patients will respond well – or not – to this kind of treatment may allow for better, more personalized therapeutic approaches, but this is easier said than done. “At present, clinicians have no way of knowing, prior to treatment, which of our newly diagnosed or relapsed ovarian cancer patients will respond or not to approved drug therapies,” a study co-author, Larry Maxwell, MD, who is the co-director of Inova’s Women’s Health Integrated Research Center, said in a press release. Researchers tested an assay that may help differentiate between ovarian cancer patients who will or won't respond to therapy, relying on three-dimensional ex vivo tissue culture. Essentially, cancer cells are taken from the patient (via biopsy or as part of surgery
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *